No. 1 is K-US500X-C(A) +22.61%
KTAM US Small Cap Equity Passive Fund
Shows where this fund stands in its group. Not investment advice · Data as of 3 Nov 2026
KT-USSM-A invests through the master fund Vanguard Morningstar Small-Cap ETF (VB) 97.74%
This fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Data as of 30 Sep 2026 · Top 6 shown, the rest grouped as Other · per the issuer's fact sheet
Over the past year it was in the top 25% of its group; there is no rank for a longer period yet
No. 1 is K-US500X-C(A) +22.61%
Each bar is one fund in the AIMC US Equity group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 3 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | MAX |
|---|---|---|---|---|---|---|---|
| +12.04% | +0.55% | +1.45% | +1.05% | −2.62% | +2.37% | +12.60% | +37.86% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan | Feb | Mar | Apr | May | Jun |
|---|
Largest drawdown in the selected period −8.06% Previous peak 14 Aug 2026 (NAV 14.5676) → Trough 14 Oct 2026 (NAV 13.3932) · Not back to the previous peak as of 3 Nov 2026
Currently −5.37% from the peak NAV of 14.5676 (14 Aug 2026)
Over 1 year, KT-USSM-A returned 0.79 per unit of volatility, ranking 16 of 83 funds · The highest is KKP EWUS500-UH (1.68)
กองทุนมีนโยบายเน้นลงทุนในหน่วยลงทุนของกองทุน Vanguard Morningstar Small-Cap ETF (กองทุนหลัก) เพียงกองทุนเดียว โดยเฉลี่ยในรอบปีบัญชีไม่น้อยกว่าร้อยละ 80 ของมูลค่าทรัพย์สินสุทธิของกองทุน โดยกองทุนหลักเป็นกองทุนอีทีเอฟ จดทะเบียนซื้อขายในตลาดหลักทรัพย์ NYSE Arca ประเทศสหรัฐอเมริกา บริหารจัดการโดย The… Its largest holdings are หน่วยลงทุน Vanguard Morningstar Small-Cap ETF 98.46% (fact sheet 30 Sep 2026)
Risk level 6 of 8 (High risk). Since 10 Apr 2025, its NAV has fallen as much as −8.06% from its peak.
Actual total expense ratio (TER) 1.08% a year, against a ceiling of 5.35%. Management fee 0.54%. Front-end fee 0.50%. Back-end fee 0.00%. (Fact sheet 31 Aug 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Minimum first purchase 1 THB, subsequent purchases 1 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+2
Hedged at the manager's discretion. As of 30 Sep 2026, 71.41% of the value of its foreign investments was hedged
They are share classes of the same fund and invest in the same assets. They differ only in each class's terms, such as dividend policy, fees or who can buy · KT-USSM-A: no dividends, TER 1.08% · KT-USSM-D: see the conditions in the prospectus · KT-USSM-I: see the conditions in the prospectus · KT-USSM-P: see the conditions in the prospectus · KT-USSM-R: see the conditions in the prospectus
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Biotech company that develops drugs for RAS-driven cancers, such as pancreatic cancer
Identity verification and single sign-on systems that let employees access apps securely
Hospitals, medicines and medical equipment
Mobile networks, internet and software
Based on the master fund's share of this fund's value (97.74% as of 31 Aug 2026) × each stock's weight in the master fund · stocks as of 22 Oct 2026 · Illustrations are for explanation only, not individual stock recommendations
| Jul |
|---|
| Aug |
|---|
| Sep |
|---|
| Oct |
|---|
| Nov |
|---|
| Dec |
|---|
| Full year |
|---|
| 2026 | +3.0 | +2.1 | −3.4 | +7.7 | +2.8 | +3.6 | −2.7 | +0.9 | −4.5 | +1.8 | +0.8 | · | +12.0* |
| 2025 | · | · | · | +7.4 | +3.9 | +3.2 | +2.0 | +3.8 | +0.6 | +0.0 | +1.0 | −0.6 | +23.0* |